Tata Elxsi has announced the establishment of a global offshore development center (ODC) for Terumo Corporation, marking a significant milestone in the company's healthcare technology partnerships. The announcement was made through a regulatory filing under Regulation 30 of SEBI regulations.

Strategic Partnership Details

The 'Terumo–Tata Elxsi Offshore Development Center' was inaugurated to support the development of Terumo's cardiac and vascular solutions. This dedicated center will strengthen engineering and innovation capabilities while enabling continuous lifecycle support across international markets.

Technology and Innovation Focus

The center brings together multidisciplinary teams, combining Tata Elxsi's expertise in design, engineering, verification, regulatory compliance, and localisation. The collaboration incorporates AI, GenAI, and digital capabilities in software engineering to enable faster development and regional adaptation while addressing the growing demand for patient-centric medical devices with improved cost efficiency and product differentiation.

Leadership Statements

Fumihisa Hirose, Company President, Cardiac & Vascular Company Terumo Corporation, stated: "This new Offshore Development Center strengthens our ability to innovate faster and deliver high-quality medical technologies across global markets. Tata Elxsi's integrated design, engineering, and regulatory expertise will help us accelerate our global product roadmap while maintaining the highest standards of safety and compliance."

Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, commented: "This Offshore Development Center represents a comprehensive long-term partnership model with Terumo Corporation to bring Tata Elxsi's multi-disciplinary, cross-functional and deep domain expertise to drive innovation and cost efficiencies across Terumo's Cardiovascular portfolio."

Market Impact

This development highlights Tata Elxsi's strategic focus on building long-term partnerships with global healthcare and medical device companies. The collaboration advances the reliability and performance of cardiac and vascular technologies, supporting their global availability and helping ensure they meet industry standards and the evolving needs of healthcare providers and patients.

Tata Elxsi Limited has received an Income Tax Assessment Order for Assessment Year 2023-24 with a total demand of ₹178.62 lakhs. The company disclosed this development under Regulation 30 of the SEBI Listing Regulations on March 06, 2026.

Assessment Order Details

The Income Tax Assessment Order was issued under section 143(3) by the Assessing Officer – Income Tax Assessment Unit. The company received the order on March 06, 2026, which resulted in the significant tax demand.

Nature of Disallowances

The tax demand stems from specific disallowances made by the Income Tax Department. The assessment order includes disallowance of foreign tax credit and 80G benefit that were claimed by the company during the assessment year.

Company's Response and Next Steps

Tata Elxsi has expressed strong disagreement with the assessment order, characterizing it as arbitrary and unsustainable under law. The company has announced its intention to challenge the order through the appropriate legal channels.

Planned Action:

• Filing an appeal with the Commissioner of Income Tax (Appeals)
• Contesting the disallowances based on legal grounds

Financial Impact

The total demand amount of ₹178.62 lakhs represents the quantifiable monetary impact on the company. However, Tata Elxsi's decision to appeal suggests confidence in its position regarding the disputed tax matters.

The disclosure was made in compliance with SEBI Listing Regulations, ensuring transparency with stakeholders regarding this regulatory development. The company's legal challenge indicates it believes the assessment contains errors that can be successfully contested at the appellate level.